Bionexo announces a new investment in the company
Company is receiving a R$ 95 million investment; funds will be used to accelerate the development of new digital healthcare solutions
São Paulo, December 14, 2018 – Bionexo, a Brazilian multinational company focused on digital solutions for the healthcare industry, is pleased to announce a R$95 million investment by Temasek. The capital raised will support the Company’s growth by strengthening its capability to offer new digital solutions for the healthcare industry and its stakeholders. The control of the Company will continue to be shared between Maurício De Lázzari Barbosa (founding partner) and Prisma Capital.
The hospital healthcare segment is experiencing an ongoing process of professionalization, coupled with a growing demand for efficiency and transparency. The industry is in the beginning stages of a digital transformation which will impact the routine of institutions and society as a whole. Bionexo is a pioneer in its market and, with this investment, will further strengthen its leadership position. Currently, the Company serves more than 1,600 healthcare institutions and 10,000 suppliers in five countries.
“Bionexo was founded in 2000, offering solutions for healthcare institutions in Brazil to negotiate their procurement online, and since then we’ve built an ecosystem through our highly credible brand. We’ve managed to grow with limited access to capital. Now, after reaching the R$10 billion mark of transaction volume in our marketplace in 2018, we felt it was the right time to bring in a new partner to help accelerate our ability to roll out new product offerings thereby contributing to the digitization of the healthcare industry,” said Maurício De Lázzari Barbosa, founder and Chairman of Bionexo.
In 2017, Bionexo began a process of corporate restructuring with the entry of Prisma Capital into its capital table, which resulted in the re-alignment of its long-term vision and objectives. Now, the Company is happy to welcome Temasek as its new partner, and is honored by their investment, not only because of Temasek’s prestige, but also because of the experience it brings to the table given its global technology experience.
Since 2017, Bionexo has significantly increased its technology team dedicated to the development of digital solutions. Looking forward, the Company intends to accelerate initiatives related to innovation and incorporate new technologies with disruptive potential for the sector.
“With this new capitalization, we intend to further strengthen our value proposition – based on efficiency, transparency and intelligence – for all our stakeholders, including hospitals, suppliers and distributors. In 2019 alone, we intend to double the number of engineers dedicated to software development, reaching the mark of 150 people,” explains Bionexo CEO Rodrigo Borer.
Bionexo is a technology company that offers digital solutions for process management in healthcare. Bionexo’s marketplace connects around 1,600 healthcare institutions and more than 10,000 suppliers, with R$ 10 billion in annual transactions. The company is a benchmark in building digital cloud solutions for healthcare and promoting innovation in the sector, decisively contributing to the professionalization and digitalization of the healthcare chain in Brazil and in the other countries in which it operates – Argentina, Colombia, Mexico and Spain.
Incorporated in 1974, Temasek is a global investment company headquartered in Singapore. Our Temasek Charter defines our roles as an investor, institution and steward, to shape our investment stance, ethos, and long term philosophy. We aim to do well, do right, and do good as a responsible and trusted member of the wider community. Supported by our network of international offices in 11 locations in Asia, Americas and Europe, Temasek is the owner of a S$308 billion (US$235b) portfolio as at 31 March 2018, with some two thirds underlying exposure to Singapore and the rest of Asia.
Our investment activities are guided by four key themes and the long term trends they represent:
Growing Middle Income Populations;
Deepening Comparative Advantages; and